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Assessment of antigen-specific humoral immunity (IgG)
is established and used clinically, whereas the analysis of
antigen-specific cellular immunity is not applied as a rou-
tine clinical test, due to the complexity of assay proce-
dures. Antigen specificity in cellular immunity means
peptide specificity on an autologous major histocompat-
ibility complex (MHC) molecule, which is recognized by
the corresponding T cell receptors (TCR). In order to
develop clinically applicable tests, we added CEF peptides
into heparinized whole blood, and incubated at 37°C
for 1-24 hours, then early responder-, immune function-
specific mRNAs were quantified by the method we
reported previously (J Immunol Methods. 363:95, 2010).
The CEF peptides are 8-12 amino acids in length, with
sequences derived from the human cytomegalovirus,
Epstein-Barr virus, and influenza virus, and used in the
stimulation of IFNg release from CD8+ T cells in ELI-
SPOT and other immune assays. In order to have ade-
quate HLA-matched antigen presenting cells in the assay,
we added peptide into whole blood, where both class
I and II MHC molecules are available on the surface of
leukocytes, which can present the peptides to autologous
peripheral blood T cells. When this experiment was done
in adult volunteers’ blood, we found significant induction
of various cytokine and chemokine mRNAs, including
IFNg, TNFa, GMCSF, IL2, CCL4, and CXCL10, whereas
the control housekeeping gene b-actin (ACTB) was not
induced all the time. The degree of induction and type of
induced mRNAs were varied considerably among indivi-
duals, suggesting the variation of immune functionality
in each individual. The induction was very rapid and
peaked around 2-4 hours. This system was successfully
tested in an NCI-sponsored clinical cancer vaccine trial
as an exploratory assay, and the induction of these
mRNAs were confirmed after 4 hours incubation with
CEF in heparinized whole blood. Moreover we also found
the induction of regulatory T cell (Treg)-related mRNAs
such as IL10, CD25, PDL1, and FOXP3 in a small percen-
tage of patient samples, suggesting the possible presence
of Treg cells. The induction of Th2-related mRNA (IL4),
myeloid-derived suppressor cells-derived mRNA (ARG1),
PD1, and CTLA4 mRNAs was not detected. In 5 patients,
where blood was obtained from Day 0 to Day 168 serially,
we also characterized the fluctuation of CEF-induced
mRNAs. Thus, the system reported here could be practi-
cally applied to clinical settings, and by selecting mRNA
species, various immune function might be assessed
quantitatively.
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